Badve, Sunil.
Sunil S. Badve
VIAF ID: 6945149489170693810005 (Personal)
Permalink: http://viaf.org/viaf/6945149489170693810005
Preferred Forms
-
-
- 100 1 _ ‡a Badve, Sunil
- 100 1 _ ‡a Badve, Sunil
-
- 100 0 _ ‡a Sunil S. Badve
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. | |
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration | |
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | |
The birth of an adenoid cystic carcinoma | |
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues | |
Counterpoint: cancer stem cells: nonbelievers' viewpoint | |
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory | |
Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast | |
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer | |
Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy | |
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer | |
The Integrated Genomic Landscape of Thymic Epithelial Tumors. | |
An international study to increase concordance in Ki67 scoring | |
ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting | |
Molecular pathology of breast cancer, 2016: | |
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database | |
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial | |
Prostanoid receptor EP1 expression in breast cancer | |
Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer | |
Reply to C. Shah et al. | |
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group | |
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning | |
Splicing factor controls ER-positive breast cancer by altering metabolic pathways | |
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study | |
Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues | |
TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters | |
Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast | |
Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). |